Growth hormone excess and the development of growth hormone receptor antagonists

Experimental Physiology

Volumn 93, Issue 11, 2008, Pages 1157-1169

  Higham, C E ^a   Trainer, P J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE RECEPTOR; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PERGOLIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; BINDING AFFINITY; CLINICAL FEATURE; CLINICAL TRIAL; COLON CANCER; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTRITIS; GENE MUTATION; GLUCOSE METABOLISM; GROWTH HORMONE RELEASE; HUMAN; HYPERTENSION; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PATHOGENESIS; PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE;

EID: 53949088064     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2008.042515     Document Type: Review

References (73)

1. Abdel-Meguid SS, Shieh HS, Smith WW, Dayringer HE, Violand BN & Bentle LA (1987). Three-dimensional structure of a genetically engineered variant of porcine growth hormone. Proc Natl Acad Sci USA 84, 6434 6437.
2. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE et al. (2005). Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90, 5684 5691.
3. Bates AS, Van't Hoff W, Jones JM & Clayton RN (1993). An audit of outcome of treatment in acromegaly. Q J Med 86, 293 299.
4. Bengtsson BA, Eden S, Ernest L, Oden A & Sjorgren B (1988). Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223, 327 335.
5. Biermasz NR, Dulken HV & Roelfsema F (2000). Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Clin Endocrinol (Oxf) 53, 321 327.
6. Brian SR, Bidlingmaier M, Wajnrajch MP, Weinzimer SA & Inzucchi SE (2007). Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 92, 3374 3377.
7. Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K et al. (2005). Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 12, 814 821.
8. Bruns C, Lewis I, Briner U, Meno-Tetang G & Weckbecker G (2002). SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146, 707 716.
9. Chen NY, Chen WY & Kopchick JJ (1996). A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin. Endocrinology 137, 5163 5165.
10. Chen WY, Chen NY, Yun J, Wagner TE & Kopchick JJ (1994). In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J Biol Chem 269, 15892 15897.
11. Chen WY, White ME, Wagner TE & Kopchick JJ (1991a). Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice. Endocrinology 129, 1402 1408.
12. Chen WY, Wight DC, Mehta BV, Wagner TE & Kopchick JJ (1991b). Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Mol Endocrinol 5, 1845 1852.
13. Chen WY, Wight DC, Wagner TE & Kopchick JJ (1990). Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci USA 87, 5061 5065.
14. Cunningham BC & Wells JA (1991). Rational design of receptor-specific variants of human growth hormone. Proc Natl Acad Sci USA 88, 3407 3411.
15. Dagnaes-Hansen F, Duan H, Rasmussen LM, Friend KE & Flyvbjerg A (2004). Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. Anticancer Res 24, 3735 3742.
16. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA et al. (2007). Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 92, 1891 1896.
17. de Vos AM, Ultsch M & Kossiakoff AA (1992). Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306 312.
18. Drake WM, Grossman AB & Hutson RK (2005). Effect of treatment with pegvisomant on meningioma growth in vivo. Eur J Endocrinol 152, 161 162.
19. Drake WM, Parkinson C, Akker SA, Monson JP, Besser GM & Trainer PJ (2001). Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur J Endocrinol 145, 451 456.
20. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA & van der Lely AJ (2005). Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365, 1644 1646.
21. Feenstra J, van Aken MO, de Herder WW, Feelders RA & van der Lely AJ (2006). Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur J Endocrinol 154, 805 806.
22. Flyvbjerg A, Bennett WF, Rasch R, Kopchick JJ & Scarlett JA (1999). Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes 48, 377 382.
23. Friend KE, Radinsky R & McCutcheon IE (1999). Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg 91, 93 99.
24. Frystyk J (2004). Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 14, 337 375.
25. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV & Wells JA (1992). Rational design of potent antagonists to the human growth hormone receptor. Science 256, 1677 1680.
26. Gent J, van Kerkhof P, Roza M, Bu G & Strous G (2002). Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc Natl Acad Sci USA 99, 9858 9863.
27. Gittoes NJ, Sheppard MC, Johnson AP & Stewart PM (1999). Outcome of surgery for acromegaly - the experience of a dedicated pituitary surgeon. QJM 92, 741 745.
28. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group (2001). The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 108, 2266 2272.
29. Guistina A & Velduis JD (1998). Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19, 717 797.
30. Harding PA, Wang X, Okada S, Chen WY, Wan W & Kopchick JJ (1996). Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization. J Biol Chem 271, 6708 6712.
31. Hartman ML, Pincus SM, Johnson ML, Matthews DH, Faunt LM, Vance ML, Thorner MO & Veldhuis JD (1994). Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release. J Clin Invest 94, 1277 1288.
32. Herman-Bonert VS, Zib K, Scarlett JA & Melmed S (2000). Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 85, 2958 2961.
33. Ilondo MM, Damholt AB, Cunningham BA, Wells JA, De Meyts P & Shymko RM (1994). Receptor dimerization determines the effects of growth hormone in primary rat adipocytes and cultured human IM-9 lymphocytes. Endocrinology 134, 2397 2403.
34. Jackson SN, Fowler J & Howlett TA (1997). Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol (Oxf) 46, 745 749.
35. Jenkins PJ & Besser M (2001). Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab 86, 2935 2941.
36. Jørgenson JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristenson LØ, Hagen C & Ørskov H (2005). Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90, 5627 5631.
37. Khandwala HM, McCutcheon IE, Flyvbjerg A & Friend KE (2000). The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21, 215 244.
38. Kopchick JJ, Parkinson C, Stevens EC & Trainer PJ (2002). Growth hormone receptor antagonists: discovery, development and use in patients with acromegaly. Endocr Rev 23, 623 646.
39. Lanzetta P & Malara C (2000). Cotherapy with recombinant human IGF-I and insulin improves glycemic control in type I diabetes. Diabetes Care 23, 436 437.
40. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR & Shalet SM (1998). The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf) 49, 653 657.
41. Maamra M, Finidori J, Von Laue S, Simon S, Justice S, Webster J, Dower S & Ross R (1999). Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signalling. J Biol Chem 274, 14791 14798.
42. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R et al. (2005). Consensus statement: medical management of acromegaly. Eur J Endocrinol 153, 737 740.
43. Moller N, Schmitz O, Jørgensen OL, Astruo J, Bak JF, Christensen SE, Alberti GMM & Weeke J (1992). Basal and insulin stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 74, 1012 1019.
44. Murray RD & Melmed S (2008). A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab May 13, Epub ahead of print.
45. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A & Trainer PJ (2003). Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88, 5650 5655.
46. Pearce KH Jr., Cunningham BC, Fuh G, Teeri T & Wells JA (1999). Growth hormone binding affinity for its receptor surpasses the requirements for cellular activity. Biochemistry 38, 81 89.
47. Pollak M, Blouin MJ, Zhang JC & Kopchick JJ (2001). Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer 85, 428 430.
48. Renehan AG, O'Connell J, O'Halloran D, Shanahan F, Potten CS, O'Dwyer ST & Shalet SM (2003). Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res 35, 712 725.
49. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM & Egger M (2004). Insulin-like growth factor (IGF-I), IGF binding protein-3 and cancer risk: systemic review and meta-regression analysis. Lancet 363, 1346.
50. Rosenfeld RG, Rosenbloom AL & Guevara-Aguirre J (1994). Growth hormone insensitivity due to primary GH receptor deficiency. Endocr Rev 15, 369 390.
51. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ & Ho KK (2001). Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 86, 1716 1723.
52. Rowlinson SW, Behncken SN, Rowland JE, Clarkson RW, Strasburger CJ, Wu Z, Baumbach W & Waters MJ (1998). Activation of chimeric and full-length growth hormone receptors by growth hormone receptor monoclonal antibodies. A specific conformational change may be required for full-length receptor signaling. J Biol Chem 273, 5307 5314.
53. Schade R, Andersohn F, Suissa S, Haverkamp W & Garbe E (2007). Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356, 29 38.
54. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B & Strasburger CJ the German Pegvisomant Investigators (2007). Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156, 75 82.
55. Seubert N, Royer Y, Staerk J, Kubatzky KF, Moucadel V, Krishnakumar S, Smith SO & Constantinescu SN (2003). Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell 12, 1239 1250.
56. Shen Q, Lantvit DD, Lin Q, Li Y, Christov K, Wang Z et al. (2007). Advanced rat mammary cancers are growth hormone dependent. Endocrinology 148, 4536 4544
57. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D et al. (1997). Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276, 1706 1709.
58. Snyder PJ, Fowble BF, Schatz NJ, Savino PJ & Gennarelli TA (1986). Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 81, 457 462.
59. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS et al. (1999). Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 84, 2098 2103.
60. Tou JS, Kaempfe LA, Vineyard BD, Buonomo FC, Della-Fera MA & Baile CA (1986). Amphiphilic growth hormone releasing factor (GRF) analogs: peptide design and biological activity in vivo. Biochem Biophys Res Commun 139, 763 770.
61. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ et al. (2000). Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 20, 1171 1177.
62. Trainer PJ, Drake WM, Perry LA, Taylor NF, Besser GM & Monson JP (2001). Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J Clin Endocrinol Metab 86, 2989 2992.
63. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L et al. (2001). Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358, 1754 1759.
64. Van der Lely AJ & Kopchick JJ (2006). Growth hormone receptor antagonists. Neuroendocrinology 83, 264 268.
65. th Annual Meeting of the Endocrine Society, New Orleans, LA, USA p. 57 (Abstract OR4-1).
66. Wan Y, McDevitt A, Shen B, Smythe ML & Waters MJ (2004). Increased site 1 affinity improves biopotency of porcine growth hormone. Evidence against diffusion dependent receptor dimerization. J Biol Chem 279, 44775 44784.
67. Wang X, Darus CJ, Xu BC & Kopchick JJ (1996). Identification of growth hormone receptor (GHR) tyrosine residues required for GHR phosphorylation and JAK2 and STAT5 activation. Mol Endocrinol 10, 1249 1260.
68. Wang Z, Luque RM, Kineman RD, Ray VH, Christov KT, Lantvit DD et al. (2008). Disruption of growth hormone signalling retards prostate carcinogenesis in the Probasin/Tag rat. Endocrinology 149, 1366 1376
69. Williams RM, Amin R, Shojaee-Moradie F, Umpleby AM, Acerini CL & Dunger DB (2003). The effects of a specific growth hormone antagonist on overnight insulin requirements and insulin sensitivity in young adults with Type 1 diabetes mellitus. Diabetologia 46, 1203 1210.
70. Wilson ME (2000). Insulin-like growth factor I (IGF-I) replacement during growth hormone receptor antagonism normalizes serum IGF-binding protein-3 and markers of bone formation in ovariectomized rhesus monkeys. J Clin Endocrinol Metab 85, 1557 1562.
71. Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA & Sharma A (2007). Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 13, 1000 1009.
72. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S & Pezzoli G (2007). Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356, 39 46.
73. Zhang X, Mehta R, Lantvit D, Coschingo K, Kopchick JJ, Green J et al. (2007). Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling. Carcinogenesis 28, 143 150.